Irbesartan (Avapro), an angiotensin II receptor blocker (ARB), reduces 24-hour systolic and diastolic blood pressure as well as albumin excretion rate (AER) in people with type 2 diabetes.

Researchers at the University of Naples in Naples, Italy, observed 64 men with type 2 who had an average age of 60 years as well as similar body mass indexes, A1C levels and diabetes duration. The men were divided into two groups: those with microalbuminuria (abnormal levels of the protein albumin in the urine) and high blood pressure and those with microalbuminuria and normal blood pressure.

Participants received either 150 mg doses of Avapro twice daily or a placebo for 60 days. After 15 days of washout, the placebo group also received Avapro.

In participants with microalbuminuria and high blood pressure, Avapro reduced 24-hour systolic and diastolic pressure and AER. In participants with microalbuminuria and normal blood pressure, Avapro reduced AER.

The researchers conclude that Avapro's beneficial effects on AER are independent of its anti-hypertensive effects.

Previous research has also demonstrated that the ACE inhibitor drug class can provide the same benefit.

—Diabetes Care, November 2002